• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    eJHaem - 2024 - Fox - Real‐world ...
    Size:
    437.4Kb
    Format:
    PDF
    Description:
    Found with Open Access Button
    Download
    Authors
    Fox, C. P.
    Townsend, W.
    Gribben, J. G.
    Menne, T.
    Kalakonda, N.
    Williams, P.
    Toron, F.
    Tyas, E.
    Cooper, M.
    Rickards, J.
    Radford, John
    Show allShow less
    Affiliation
    Manchester Academic Health Science Centre The Christie NHS Foundation Trust and University of Manchester Manchester UK.
    Issue Date
    2024
    
    Metadata
    Show full item record
    Abstract
    Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.
    Citation
    Fox CP, Townsend W, Gribben JG, Menne T, Kalakonda N, Williams P, et al. Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England. EJHaem. 2024 Oct;5(5):992-7. PubMed PMID: 39415902. Pubmed Central PMCID: PMC11474359. Epub 2024/10/17. eng.
    Journal
    EJHaem
    URI
    http://hdl.handle.net/10541/627284
    DOI
    10.1002/jha2.970
    PubMed ID
    39415902
    Additional Links
    https://dx.doi.org/10.1002/jha2.970
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1002/jha2.970
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.
    • Authors: Puckrin R, Stewart DA, Shafey M
    • Issue date: 2022 Apr
    • Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.
    • Authors: Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB
    • Issue date: 2024 Oct
    • Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
    • Authors: Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F
    • Issue date: 2023 Oct
    • Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    • Authors: Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB
    • Issue date: 2022 Sep
    • Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
    • Authors: Saeedian M, Badaracco J, Botros A, Gitlin M, Keating SJ
    • Issue date: 2023 Nov
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.